Suppr超能文献

前列腺素 E2 敏感受体对调节常规流出的人眼细胞收缩性的差异影响。

Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow.

机构信息

Department of Biological Sciences, Allergan, Inc., Irvine, California 92612, USA.

出版信息

Invest Ophthalmol Vis Sci. 2013 Jul 16;54(7):4782-90. doi: 10.1167/iovs.13-12363.

Abstract

PURPOSE

The goal of this study was to functionally compare prostaglandin E2 (PGE2)-sensitive receptors in human primary cells involved in conventional outflow.

METHODS

The expression profile of prostaglandin (PG) receptors in primary cultures of human trabecular meshwork (TM) and Schlemm's canal (SC) cells were determined by quantitative-PCR. The functional activities of endogenous PGE2-sensitive receptors were evaluated using subtype-selective agonists and antagonists with cell impedance technology.

RESULTS

Agonist-sensitive EP1, EP2, and EP4 receptors were present in TM cells, all increasing cell stiffness (or contractility) in a dose-dependent manner. Rank order of efficacy (Emax) for agonists in TM cells were EP1 greater than EP2 greater than EP4 with EC50 1.1 μM, 0.56 μM, and 0.1 μM, respectively, and no functional EP3 receptors were found. Of the four EP receptor subtypes active in SC cells, EP1 and EP3 receptor activation increased cell stiffness, while EP2 and EP4 agonists dose-dependently decreased cell stiffness 47% and 23% with EC50 values of 170 nM and 69 nM, respectively. Consistent with these observations, the Rho kinase inhibitor Y-27632 decreased cell impedance (stiffness) of TM and SC cells (∼60%), while Rho GTPase activator thrombin caused cell impedance to increase in both cell types (168%-190%).

CONCLUSIONS

Cell impedance positively correlates with cellular stiffness/contractility. Because EP2/4 receptors caused decreased cell stiffness in SC, but not in TM cells, both receptors appear to mediate IOP lowering via changes in SC cell stiffness in the conventional outflow pathway.

摘要

目的

本研究旨在从功能上比较参与传统流出途径的人原发性细胞中前列腺素 E2(PGE2)敏感受体。

方法

通过定量 PCR 确定人小梁网(TM)和 Schlemm 管(SC)细胞原代培养物中前列腺素(PG)受体的表达谱。使用亚型选择性激动剂和拮抗剂通过细胞阻抗技术评估内源性 PGE2 敏感受体的功能活性。

结果

TM 细胞中存在激动剂敏感的 EP1、EP2 和 EP4 受体,所有受体均以剂量依赖性方式增加细胞硬度(或收缩性)。TM 细胞中激动剂的效价(Emax)顺序为 EP1 大于 EP2 大于 EP4,EC50 分别为 1.1 μM、0.56 μM 和 0.1 μM,并且未发现功能性 EP3 受体。在 SC 细胞中四种 EP 受体亚型中,EP1 和 EP3 受体的激活增加了细胞硬度,而 EP2 和 EP4 激动剂则以剂量依赖性方式使细胞硬度分别降低了 47%和 23%,EC50 值分别为 170 nM 和 69 nM。与这些观察结果一致,Rho 激酶抑制剂 Y-27632 降低了 TM 和 SC 细胞的细胞阻抗(硬度)(约 60%),而 Rho GTPase 激活剂凝血酶使两种细胞类型的细胞阻抗增加(168%-190%)。

结论

细胞阻抗与细胞硬度呈正相关。由于 EP2/4 受体使 SC 细胞的硬度降低,但 TM 细胞没有,因此这两种受体似乎通过改变 SC 细胞在传统流出途径中的硬度来介导眼压降低。

相似文献

2
Cellular basis for bimatoprost effects on human conventional outflow.
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5176-81. doi: 10.1167/iovs.09-4955. Epub 2010 Apr 30.
5
Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle.
Exp Eye Res. 1997 Mar;64(3):447-53. doi: 10.1006/exer.1996.0224.
8
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Exp Cell Res. 2003 Oct 1;289(2):265-74. doi: 10.1016/s0014-4827(03)00269-6.

引用本文的文献

1
Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation.
Drug Des Devel Ther. 2025 Jan 31;19:703-714. doi: 10.2147/DDDT.S506520. eCollection 2025.
2
Prostaglandin analogs in ophthalmology.
Indian J Ophthalmol. 2023 May;71(5):1768-1776. doi: 10.4103/IJO.IJO_2706_22.
3
Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress.
J Nanobiotechnology. 2023 Mar 10;21(1):84. doi: 10.1186/s12951-023-01838-x.
4
Medical Therapy and Scleral Windows for Uveal Effusion Syndrome: A Case Series and Literature Review.
Ophthalmol Ther. 2023 Feb;12(1):35-53. doi: 10.1007/s40123-022-00601-z. Epub 2022 Nov 21.
5
Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma.
Front Pharmacol. 2022 Oct 12;13:1015338. doi: 10.3389/fphar.2022.1015338. eCollection 2022.
6
The Piezo1 ion channel in glaucoma: a new perspective on mechanical stress.
Hum Cell. 2022 Sep;35(5):1307-1322. doi: 10.1007/s13577-022-00738-w. Epub 2022 Jun 29.
8
Effect of Prostaglandin E2 Agonist Omidenepag on the Expression of Matrix Metalloproteinase in Trabecular Meshwork Cells.
Korean J Ophthalmol. 2022 Apr;36(2):123-130. doi: 10.3341/kjo.2021.0169. Epub 2022 Jan 24.
9
Evidence for Menopause as a Sex-Specific Risk Factor for Glaucoma.
Cell Mol Neurobiol. 2023 Jan;43(1):79-97. doi: 10.1007/s10571-021-01179-z. Epub 2022 Jan 4.

本文引用的文献

1
PGE2 differentially regulates monocyte-derived dendritic cell cytokine responses depending on receptor usage (EP2/EP4).
Mol Immunol. 2013 Jul;54(3-4):284-95. doi: 10.1016/j.molimm.2012.12.010. Epub 2013 Jan 20.
2
Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes.
Invest Ophthalmol Vis Sci. 2012 Aug 24;53(9):5838-45. doi: 10.1167/iovs.12-9923.
6
The role of the prostaglandin EP4 receptor in the regulation of human outflow facility.
Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3506-13. doi: 10.1167/iovs.10-6510.
7
Cellular basis for bimatoprost effects on human conventional outflow.
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5176-81. doi: 10.1167/iovs.09-4955. Epub 2010 Apr 30.
8
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3320-8. doi: 10.1167/iovs.08-3031. Epub 2009 Feb 21.
9
Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.
J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8. doi: 10.1089/jop.2008.0089.
10
Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists.
Bioorg Med Chem Lett. 2009 Feb 1;19(3):778-82. doi: 10.1016/j.bmcl.2008.12.027. Epub 2008 Dec 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验